Want to see IN:MOREPENLAB full AI Analyst Report?
MOREPENLAB Stock Chart & Stats
₹41.99
-₹1.18(-1.56%)
At close: 4:00 PM EST
₹41.99
-₹1.18(-1.56%)
Day’s Range― - ―
52-Week Range₹33.42 - ₹123.50
Previous CloseN/A
Volume3.34M
Average Volume (3M)1.48M
Market Cap
₹66.11B
Enterprise Value₹19.69K
Total Cash (Recent Filing)₹916.99M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)47.2
Beta1.77
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.17%
Share Statistics
EPS (TTM)2.56
Shares Outstanding547,953,700
10 Day Avg. Volume1,255,073
30 Day Avg. Volume1,476,548
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)1.64
Price to Sales (P/S)1.13
P/FCF Ratio-14.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Pharmaceutical And Diagnostics ModelExposure to APIs, finished formulations, and consumer diagnostics gives Morepen Laboratories multiple revenue channels across business-to-business and branded healthcare markets. This breadth can support resilience through differing product cycles and creates potential for recurring consumables demand from an installed device base.
Improved Earnings ProfileThe recovery from the 2023 earnings trough and continued positive net income through 2026 indicate improved operating performance and a more stable profit base. Sustained profitability strengthens the company’s ability to reinvest in products, manufacturing capabilities, and market expansion over coming quarters.
Moderate Leverage And Growing Equity BaseA substantial equity base and still-moderate leverage provide financial support for ongoing operations and investment, while reducing dependence on aggressive borrowing. This balance-sheet foundation can improve resilience during industry fluctuations, even though recent debt growth has reduced flexibility compared with prior years.
Bears Say
Persistent Negative Free Cash FlowPersistent negative free cash flow shows that reported earnings are not converting into sufficient internally generated cash. This can constrain funding for growth, increase reliance on external capital, and weaken financial flexibility if the cash-conversion problem continues across the next several quarters.
Recent Margin CompressionMargin compression suggests that the recent earnings improvement is not being supported by steady operating leverage or expanding profitability. If margins remain under pressure, Morepen Laboratories may generate less profit from each unit of revenue and have less capacity to absorb cost or pricing pressures.
Debt Increased Materially In The Latest YearThe recent increase in total debt adds financial commitments at a time when free cash flow remains negative. Although leverage is still described as moderate, higher borrowing can limit capital-allocation flexibility and make sustained investment more dependent on improving cash generation.
Morepen Laboratories Limited News
MOREPENLAB FAQ
What was Morepen Laboratories Limited’s price range in the past 12 months?
Morepen Laboratories Limited lowest stock price was ₹33.42 and its highest was ₹123.50 in the past 12 months.
What is Morepen Laboratories Limited’s market cap?
Morepen Laboratories Limited’s market cap is ₹66.11B.
When is Morepen Laboratories Limited’s upcoming earnings report date?
Morepen Laboratories Limited’s upcoming earnings report date is Nov 05, 2026 which is in 47 days.
How were Morepen Laboratories Limited’s earnings last quarter?
Morepen Laboratories Limited released its earnings results on Aug 04, 2026. The company reported ₹1.029 earnings per share for the quarter.
Is Morepen Laboratories Limited overvalued?
According to Wall Street analysts Morepen Laboratories Limited’s price is currently Overvalued.
Does Morepen Laboratories Limited pay dividends?
Morepen Laboratories Limited pays a Annually dividend of ₹0.2 which represents an annual dividend yield of 0.17%. See more information on Morepen Laboratories Limited dividends here
What is Morepen Laboratories Limited’s EPS estimate?
Morepen Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Morepen Laboratories Limited have?
Morepen Laboratories Limited has 547,953,700 shares outstanding.
What happened to Morepen Laboratories Limited’s price movement after its last earnings report?
Morepen Laboratories Limited reported an EPS of ₹1.029 in its last earnings report. Following the earnings report the stock price went up 19.99%.
Which hedge fund is a major shareholder of Morepen Laboratories Limited?
Currently, no hedge funds are holding shares in IN:MOREPENLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Morepen Laboratories Limited
Morepen Laboratories Limited is an Indian pharmaceutical company primarily engaged in the development, manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs), proprietary and generic pharmaceutical formulations, and a diverse range of home healthcare products. Its API portfolio encompasses compounds utilized in the creation of drugs for conditions such as allergies, asthma, elevated cholesterol, hypertension, and diabetes. The company also supplies an array of point-of-care and medical devices for home use, including diagnostic tools like air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse oximeters, nebulizers, glucometers with accompanying strips, as well as hygiene products such as sanitizers, disinfectant solutions, masks, and gloves. Among its well-known branded products are Burnol, a cream for treating burns; Lemolate, an offering for cough and cold relief; and Fiber-X, a psyllium husk supplement. Furthermore, Morepen produces finished drug formulations covering various therapeutic areas, including gastrointestinal health, antibiotics, vitamins, nutritional support, anti-diabetics, and cardiovascular conditions. Beyond these offerings, the company undertakes contract manufacturing for other businesses and participates in brand sharing agreements. Its comprehensive range of over-the-counter (OTC) products is marketed under the recognizable Dr. Morepen brand. The company's global footprint extends to approximately 75 nations, where its products are exported. Established in 1984, Morepen Laboratories Limited maintains its headquarters in New Delhi, India.
Technical Analysis
Alembic Limited
―
Hikal Limited
―
Indoco Remedies Limited
―
Solara Active Pharma Sciences Ltd.
―
Windlas Biotech Ltd.
―







